Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or
the “Company”), a clinical-stage drug development company
pioneering transformative medicines that target the endocannabinoid
system, today announced the presentation of three abstracts at the
American College of Rheumatology (“ACR”) Convergence 2020 being
held online, November 5–9, 2020.
The full list of lenabasum presentations at ACR
Convergence 2020 includes:
Abstract #1639: Preliminary Baseline Subject
Demographics and Disease Characteristics in a Phase 3 Clinical
Trial of the Safety and Efficacy of Lenabasum in Dermatomyositis
(DETERMINE) Session: Miscellaneous Rheumatic &
Inflammatory Diseases Poster 3: Therapies Date:
Monday, November 9, 2020 Presentation Time: 9:00
a.m. - 11:00 a.m. ETPresenter: Victoria Werth,
M.D., Professor of Dermatology and Medicine at the University of
Pennsylvania Perelman School of Medicine and Co-Principal
Investigator of Corbus' Phase 3
DETERMINE study in
dermatomyositis
Abstract #1949: CB2 Receptor Distribution and
Effects of Lenabasum in Dermatomyositis In Vitro
Session: Cytokines & Cell Trafficking
(1948–1952) Date: Monday, November 9, 2020
Presentation Time: 3:00 p.m. - 3:50 p.m.
ETPresenter: Spandana Maddukuri, University of
Pennsylvania and the Michael J. Crescenz VA Medical Center
Abstract # 1379: Clinical
Outcomes Among Participants with Diffuse Systemic Sclerosis
Contracting COVID-19 During Clinical Studies of Lenabasum: A Case
Series Session: Systemic Sclerosis & Related
Disorders – Clinical Poster 3 Date: Sunday,
November 8, 2020 Presentation Time: 9:00 a.m. -
11:00 a.m. ET Presenter: Robyn Domsic, M.D., MPH,
Associate Professor of Medicine in the Division of Rheumatology and
Clinical Immunology at the University of Pittsburgh School of
Medicine and investigator of Corbus’ Phase 3 RESOLVE-1 study in
systemic sclerosis
The ACR abstracts are available online at the
conference website. Information from the ACR presentations are
under embargo until November 5, 2020 at 2:00 p.m. ET. Once the
posters are made public, they will be available on the Company’s
website in the Scientific Conferences section.
About Lenabasum
Lenabasum is a novel, oral, small molecule that
selectively binds as an agonist to the cannabinoid receptor type 2
(CB2) and resolves inflammation and limits fibrosis in animal and
human models of disease. CB2 is preferentially expressed on
activated immune cells and on fibroblasts, muscle cells, and
endothelial cells. Lenabasum has demonstrated acceptable safety and
tolerability profiles in clinical studies to date.
About Dermatomyositis
Dermatomyositis (DM), a form of myositis, is a
chronic, rare, inflammatory, clinically heterogenous,
life-threatening autoimmune disease affecting approximately 80,000
people in North America, EU and Japan.1 The signs and symptoms of
DM reflect multi-organ involvement, which includes distinctive skin
rashes usually accompanied by proximal muscle weakness, and can
also include pulmonary, cardiac, gastrointestinal, and joint
involvement.2 Patients with DM can have recurrent disease flares or
chronic progressive disease activity, with increased mortality.3,4
The current mainstay of treatments include FDA-approved systemic
glucocorticoids, adrenocorticotropic hormone analogue and off-label
use of glucocorticoid-sparing immunosuppressive agents.5,6 There is
significant unmet need for new treatments to achieve disease
control in DM because of limited efficacy or toxicity of
immunosuppressive agents or refractory disease.7,8
About Systemic Sclerosis
Systemic sclerosis, a form of scleroderma, is a
chronic, rare, debilitating autoimmune disease affecting
approximately 200,000 people in the North America, EU and Japan.1
Systemic sclerosis is considered one of the most life-threatening
rheumatic diseases.9 The disease affects the skin and internal
organs and is driven by inflammation and fibrosis (scarring of
tissue) which can lead to severe damage and failure of multiple
organs including the skin, joints, tendons, gastrointestinal tract,
lungs, heart, blood vessels and kidneys.10 There is no cure for
systemic sclerosis, and current treatments address the clinical
manifestations of the disease, not the underlying mechanisms that
drive inflammation and fibrosis.11
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a
clinical-stage company focused on the development and
commercialization of novel medicines designed to target the
endocannabinoid system. The Company’s lead product candidate,
lenabasum, is a novel, oral, selective cannabinoid receptor type 2
(CB2) agonist that resolves chronic inflammation and limits
fibrosis in animal and human models. Lenabasum is currently being
evaluated in dermatomyositis and systemic lupus erythematosus.
Corbus is also developing a pipeline of other preclinical drug
candidates from its endocannabinoid system platform.
Lenabasum is not approved for the treatment of
any indication. For more information on Corbus’ clinical programs,
please visit here.
For more information, visit http://www.corbuspharma.com/, and
connect with us on Twitter, LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and Private Securities Litigation Reform Act, as
amended, including those relating to the Company's restructuring,
trial results, product development, clinical and regulatory
timelines, market opportunity, competitive position, possible or
assumed future results of operations, business strategies,
potential growth opportunities and other statement that are
predictive in nature. These forward-looking statements are based on
current expectations, estimates, forecasts and projections about
the industry and markets in which we operate and management's
current beliefs and assumptions. These statements may be identified
by the use of forward-looking expressions, including, but not
limited to, "expect," "anticipate," "intend," "plan," "believe,"
"estimate," "potential,” "predict," "project," "should," "would"
and similar expressions and the negatives of those terms. These
statements relate to future events or our financial performance and
involve known and unknown risks, uncertainties, and other factors,
including the potential impact of the recent COVID-19 pandemic and
the potential impact of sustained social distancing efforts, on our
operations, clinical development plans and timelines, which may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company's filings with the
Securities and Exchange Commission. Prospective investors are
cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this press release.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Corbus Pharmaceuticals Contacts:
Ted Jenkins, Senior Director, Investor Relations and Corporate
CommunicationsPhone: +1 (617) 415-7745Email:
ir@corbuspharma.com
Lindsey Smith, Director, Investor Relations and Corporate
CommunicationsPhone: +1 (617) 415-7749Email:
mediainfo@corbuspharma.com
Christina TartagliaStern Investor RelationsPhone: +1 (212)
362-1200Email: christina.tartaglia@sternir.com
- Health Advances, LLC Analysis
- “Dermatomyositis Information Page.” National Institute of
Neurological Disorders and Stroke, U.S. Department of Health and
Human Services, 29 September 2020,
www.ninds.nih.gov/Disorders/All-Disorders/Dermatomyositis-Information-Page
- Marie, Isabelle. “Morbidity and Mortality in Adult Polymyositis
and Dermatomyositis.” Current Rheumatology Reports, vol. 14, no. 3,
2012, pp. 275–285., doi:10.1007/s11926-012-0249-3
- Schiopu, Elena, et al. “Predictors of Survival in a Cohort of
Patients with Polymyositis and Dermatomyositis: Effect of
Corticosteroids, Methotrexate and Azathioprine.” Arthritis Research
& Therapy, vol. 14, no. 1, 2012, doi:10.1186/ar3704
- FDA label Orapred ODT,
availableat https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021959s004lbl.pdf;
accessed 29 September 2020
- FDA label H.P. Acthar gel, available
at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/008372s057lbl.pdf;
accessed 29 September 2020
- Dalakas, Marinos C. “Immunotherapy of Myositis: Issues,
Concerns and Future Prospects.” Nature Reviews Rheumatology, vol.
6, no. 3, Mar. 2010, pp. 129–137., doi:10.1038/nrrheum.2010.2
- DeWane ME, et al. Dermatomyositis: Clinical features and
pathogenesis. J Am Acad Dermatol.
- Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in
mortality in patients with systemic sclerosis over 40 years: a
systematic review and meta-analysis of cohort studies. Rheumatology
2012;51(6):1017e26
- Sierra-Sepulveda A, Esquinca-Gonzalez A, Benavides-Suarez SA,
Sordo-Lima DE, Caballero-Islas AE, Cabral-Castaneda AR, et al.
Systemic Sclerosis Pathogenesis and Emerging Therapies, beyond the
Fibroblast. Biomed Res Int. 2019;2019:4569826
- Scleroderma.” National Institute of Arthritis and
Musculoskeletal and Skin Diseases, U.S. Department of Health and
Human Services, 29 September 2020,
www.niams.nih.gov/health-topics/scleroderma/advanced#tab-risk.
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Apr 2024 to May 2024
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From May 2023 to May 2024